GWP.L Share News (GWP)

UPDATE 2-Cannabis drug succeeds in epilepsy, doubling value of GW Pharma

* Epidiolex succeeds in Dravet syndrome clinical trial * Shares surge 125 pct on hopes for $1 billion-plus sales (Adds CEO interview, latest shares, sales forecast) By Ben Hirschler LONDON, March 14 (Reuters) - An experimental cannabis-based drug has successfully treated child

LONDON MARKET MIDDAY: Miners Lead FTSE As GW Pharmaceuticals Lifts AIM

UPDATE: GW Pharmaceuticals Shares Double On Epidiolex Trial Results

GW Pharmaceuticals rockets on positive results for Dravet epilepsy tests

(ShareCast News) - Shares in GW Pharmaceuticals rocketed up more than 120% after revealed exciting results of its cannabis-based treatment for children with a rare form of epilepsy. The company's first major paediatric epilepsy trial for its Epidiolex drug achieved its primary endpoint with high sta

GW Pharmaceuticals Sees Positive Phase III Epidiolex Study Results

GW Pharma cannabis drug succeeds in epilepsy trial, shares leap

LONDON, March 14 (Reuters) - An experimental cannabis-based drug has successfully treated children with a rare form of severe epilepsy in a keenly anticipated clinical trial, sending shares in its maker GW Pharmaceuticals 25 percent higher on Monday. The study of GW's Epidiolex in Dravet sy

GW Pharmaceuticals First Quarter Loss Widens As It Drives Pipeline

GW Pharma losses increase ahead of key epilepsy trial results

(ShareCast News) - Cannabis-derived medicines specialist GW Pharmaceuticals posted a £17.7m loss in the first quarter as it gears up to report data from four Phase 3 trials for its Epidiolex product. GW made £3.7m revenue in the three months to 31 December from its Sativex, less than half the £8.0m

Earnings, Trading Statements Calendar - Week Ahead

Marijuana Inc. eyes Mexico as drug liberalization looms

By Gabriel Stargardter MEXICO CITY, Jan 20 (Reuters) - Many top companies cashing in on legal cannabis are considering a bet on Mexico after a Supreme Court decision raised hopes for a legalization of medical and recreational marijuana in a country reeling from years of gruesome drug violen

UPDATE 5-French drug trial disaster leaves one brain dead, five injured

* All trials of drug from Portugal's Bial suspended * "This is unprecedented" - French health minister * Drug aimed at tackling mood and anxiety issues (Adds Bial reaction, minister quotes, details) By Matthias Blamont PARIS, Jan 15 (Reuters) - One person has been left b

GW Pharmaceuticals Epidiolex Data Published In Medical Journal

DIRECTOR DEALINGS: GW Pharmaceuticals Non-Executive Sells Shares

GW Pharmaceuticals Annual Loss Widens On Higher Costs, Revenue Dip

Earnings, Trading Statements Calendar - Week Ahead